| 7.6 -0.35 (-4.4%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.04 | 1-year : | 11.73 |
| Resists | First : | 8.6 | Second : | 10.04 |
| Pivot price | 5.79 |
|||
| Supports | First : | 6.29 | Second : | 4.87 |
| MAs | MA(5) : | 6.45 |
MA(20) : | 5.78 |
| MA(100) : | 4.82 |
MA(250) : | 6.51  |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 82.6 |
D(3) : | 67.3 |
| RSI | RSI(14): 72.9 |
|||
| 52-week | High : | 25.32 | Low : | 2.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BIOA ] has closed above the upper band by 5.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 337% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.06 - 8.1 | 8.1 - 8.14 |
| Low: | 7.25 - 7.29 | 7.29 - 7.33 |
| Close: | 7.52 - 7.6 | 7.6 - 7.67 |
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Wed, 22 Oct 2025
This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Wed, 22 Oct 2025
Citigroup Upgrades BioAge Labs (BIOA) - Nasdaq
Wed, 22 Oct 2025
Bioage Labs (BIOA) Upgraded to 'Buy' with Price Target Doubled b - GuruFocus
Thu, 02 Oct 2025
BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Sat, 27 Sep 2025
BioAge Labs, Inc. (NASDAQ:BIOA) institutional owners may be pleased with recent gains after 74% loss over the past year - simplywall.st
Mon, 15 Sep 2025
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 2.431e+007 (%) |
| Held by Institutions | 3.6 (%) |
| Shares Short | 2,330 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.115e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 26.9 % |
| Return on Equity (ttm) | -23.5 % |
| Qtrly Rev. Growth | 3.86e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.18 |
| Qtrly Earnings Growth | -6.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.49e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|